Cediranib
Salivary Gland Squamous Cell Carcinoma
AIDS Malignancy ConsortiumSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Salivary Gland Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab National Cancer Institute (NCI) | Phase 1 | CC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CC |
Irinotecan AIDS Malignancy Consortium | Phase 1 | CC |
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI Stanford University | Phase 1 | CC |
(+)-VINCRISTINE AIDS Malignancy Consortium | Phase 1 | CC |
Carboplatin AIDS Malignancy Consortium | Phase 1 | CC |
Vorinostat AIDS Malignancy Consortium | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →